Figure 3.
AHR activation suppresses critical genes and key transcription factors involved in B cell and dendritic cell development. (A) Dot plot of the average gene expression of TCDD-treatment induced differentially expressed genes in MPP (multipotent progenitor) cluster on days 7 and 14. All DEGs are associated with a Bonferroni adjusted P value <.05. (B) Density of cells along MPP to lymphoid cells trajectory and expression of the top 4 highly variable genes that are differentially expressed by TCDD treatment and are involved in the development of lymphoid cells. (C) Percent BCL11A protein–expressing cells in overall population from 5 independent experiments. (D) Percent BCL11A protein–expressing cells in CD10+ CD19– cells of vehicle and TCDD-treated groups across days from 5 independent experiments. (E) Transcription factor activity of IRF8 (analyzed by SCENIC) in pDC (plasmacytoid dendritic cell) cluster. Statistical significance of differences in TF activity between treatments at any time point was calculated using a Wilcoxon rank sum test. ∗P < .05. (F) Percent IRF8 protein–expressing cells in overall population from 5 independent experiments. (C-D,F) Protein expression was measured using flow cytometry. Error bars show mean ± standard error of the mean. Statistical significance of differences in percentage of cells between treatments at any time point was calculated using a 2-tailed paired t test. ∗ P < .05, ∗∗ P < .01, ∗∗∗ P < .001.

AHR activation suppresses critical genes and key transcription factors involved in B cell and dendritic cell development. (A) Dot plot of the average gene expression of TCDD-treatment induced differentially expressed genes in MPP (multipotent progenitor) cluster on days 7 and 14. All DEGs are associated with a Bonferroni adjusted P value <.05. (B) Density of cells along MPP to lymphoid cells trajectory and expression of the top 4 highly variable genes that are differentially expressed by TCDD treatment and are involved in the development of lymphoid cells. (C) Percent BCL11A protein–expressing cells in overall population from 5 independent experiments. (D) Percent BCL11A protein–expressing cells in CD10+ CD19 cells of vehicle and TCDD-treated groups across days from 5 independent experiments. (E) Transcription factor activity of IRF8 (analyzed by SCENIC) in pDC (plasmacytoid dendritic cell) cluster. Statistical significance of differences in TF activity between treatments at any time point was calculated using a Wilcoxon rank sum test. ∗P < .05. (F) Percent IRF8 protein–expressing cells in overall population from 5 independent experiments. (C-D,F) Protein expression was measured using flow cytometry. Error bars show mean ± standard error of the mean. Statistical significance of differences in percentage of cells between treatments at any time point was calculated using a 2-tailed paired t test. ∗ P < .05, ∗∗ P < .01, ∗∗∗ P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal